Market closedNon-fractional
Corvus Pharmaceuticals/CRVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Ticker
CRVS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Burlingame, United States
Employees
28
Website
www.corvuspharma.com
CRVS Metrics
BasicAdvanced
$144M
Market cap
-
P/E ratio
-$0.51
EPS
1.05
Beta
-
Dividend rate
Price and volume
Market cap
$144M
Beta
1.05
Financial strength
Current ratio
3.4
Quick ratio
3.301
Long term debt to equity
3.117
Total debt to equity
3.117
Management effectiveness
Return on assets (TTM)
-29.33%
Return on equity (TTM)
-60.46%
Valuation
Price to book
3.37
Price to tangible book (TTM)
3.37
Price to free cash flow (TTM)
-5.356
Growth
Earnings per share change (TTM)
-41.99%
3-year earnings per share growth (CAGR)
50.18%
What the Analysts think about CRVS
Analyst Ratings
Majority rating from 4 analysts.
CRVS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$5.7M
-13.64%
Profit margin
0.00%
NaN%
CRVS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.12
-$0.14
-$0.12
-
Expected
-$0.14
-$0.12
-$0.12
-$0.14
-$0.11
Surprise
0.54%
-1.64%
17.65%
-11.11%
-
CRVS News
AllArticlesVideos
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
GlobeNewsWire·2 months ago
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals (CRVS) has a market cap of $144M as of July 27, 2024.
What is the P/E ratio for Corvus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of July 27, 2024.
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Corvus Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.